KPhA Poll on 2017 Legislative Priorities

OUR KPhA and its Government Affairs Committee are seeking your input into our legislative agenda for the upcoming legislative cycle. We are asking you to rank each item with reference to the importance that item has to you, your practice and your patients. Go to https://kphanet.site-ym.com/page/AdvocateforKPhA for a synopsis intended to provide additional details to guide your priority ranking of each issue. Please rank each issue in level of importance, ranging from “Most Important” to “Not Important at All”, referencing what you think about the importance of the issue in terms of it being a legislative priority for the Association. Note that there is an option for “Neutral” on the survey for any particular item as well.

Question Title

* 1. CHFS’ has proposed regulation changes (KAR 55:035) to add gabapentin to KY’s list of Schedule V controlled substances. Do you support this change?

Yes

Question Title

* 2. OUR KPhA is asking for input on KPhA’s 2017 Legislative Agenda. We hope you are able to attend the 2016 Legislative Conference on Nov. 11 and participate in the live discussion of these items. For now, we're asking for your input on the following issues facing the profession in Kentucky. Please rate these issues from 1(most important) to 5 (least important):

	Most Important	Somewhat Important	Important	Not very important	Not important at all	Neutral
Update for Pharmacists Administering Authority for Immunizations by lowering age requirements for an immunization from age 14 to age 9.	Update for Pharmacists Administering Authority for Immunizations by lowering age requirements for an immunization from age 14 to age 9. Most Important	Update for Pharmacists Administering Authority for Immunizations by lowering age requirements for an immunization from age 14 to age 9. Somewhat Important	Update for Pharmacists Administering Authority for Immunizations by lowering age requirements for an immunization from age 14 to age 9. Important	Update for Pharmacists Administering Authority for Immunizations by lowering age requirements for an immunization from age 14 to age 9. Not very important	Update for Pharmacists Administering Authority for Immunizations by lowering age requirements for an immunization from age 14 to age 9. Not important at all	Update for Pharmacists Administering Authority for Immunizations by lowering age requirements for an immunization from age 14 to age 9. Neutral
Promote a realistic and professional sustainable fee by the MCOs for community pharmacies	Promote a realistic and professional sustainable fee by the MCOs for community pharmacies Most Important	Promote a realistic and professional sustainable fee by the MCOs for community pharmacies Somewhat Important	Promote a realistic and professional sustainable fee by the MCOs for community pharmacies Important	Promote a realistic and professional sustainable fee by the MCOs for community pharmacies Not very important	Promote a realistic and professional sustainable fee by the MCOs for community pharmacies Not important at all	Promote a realistic and professional sustainable fee by the MCOs for community pharmacies Neutral
Continuation of support of 2016's HB 458 (Mail Order and Specialty Drugs & Cessation of mail order promotion by the MCOs.)	Continuation of support of 2016's HB 458 (Mail Order and Specialty Drugs & Cessation of mail order promotion by the MCOs.) Most Important	Continuation of support of 2016's HB 458 (Mail Order and Specialty Drugs & Cessation of mail order promotion by the MCOs.) Somewhat Important	Continuation of support of 2016's HB 458 (Mail Order and Specialty Drugs & Cessation of mail order promotion by the MCOs.) Important	Continuation of support of 2016's HB 458 (Mail Order and Specialty Drugs & Cessation of mail order promotion by the MCOs.) Not very important	Continuation of support of 2016's HB 458 (Mail Order and Specialty Drugs & Cessation of mail order promotion by the MCOs.) Not important at all	Continuation of support of 2016's HB 458 (Mail Order and Specialty Drugs & Cessation of mail order promotion by the MCOs.) Neutral
Mail Order (stand alone bill)	Mail Order (stand alone bill) Most Important	Mail Order (stand alone bill) Somewhat Important	Mail Order (stand alone bill) Important	Mail Order (stand alone bill) Not very important	Mail Order (stand alone bill) Not important at all	Mail Order (stand alone bill) Neutral
Specialty Drugs (stand alone bill)	Specialty Drugs (stand alone bill) Most Important	Specialty Drugs (stand alone bill) Somewhat Important	Specialty Drugs (stand alone bill) Important	Specialty Drugs (stand alone bill) Not very important	Specialty Drugs (stand alone bill) Not important at all	Specialty Drugs (stand alone bill) Neutral
Patient care issues	Patient care issues Most Important	Patient care issues Somewhat Important	Patient care issues Important	Patient care issues Not very important	Patient care issues Not important at all	Patient care issues Neutral
Support legislation that would require the MCOs and insurances providers where applicable to reimburse the pharmacist at a provider rate and method, e.g., for Naloxone initiation therapy as one example.	Support legislation that would require the MCOs and insurances providers where applicable to reimburse the pharmacist at a provider rate and method, e.g., for Naloxone initiation therapy as one example. Most Important	Support legislation that would require the MCOs and insurances providers where applicable to reimburse the pharmacist at a provider rate and method, e.g., for Naloxone initiation therapy as one example. Somewhat Important	Support legislation that would require the MCOs and insurances providers where applicable to reimburse the pharmacist at a provider rate and method, e.g., for Naloxone initiation therapy as one example. Important	Support legislation that would require the MCOs and insurances providers where applicable to reimburse the pharmacist at a provider rate and method, e.g., for Naloxone initiation therapy as one example. Not very important	Support legislation that would require the MCOs and insurances providers where applicable to reimburse the pharmacist at a provider rate and method, e.g., for Naloxone initiation therapy as one example. Not important at all	Support legislation that would require the MCOs and insurances providers where applicable to reimburse the pharmacist at a provider rate and method, e.g., for Naloxone initiation therapy as one example. Neutral